Phase II study of 5-fluorouracil and interferon-gamma in patients with metastatic colorectal cancer. A Hellenic Cooperative Oncology Group Study

Loading...
Thumbnail Image

Date

Authors

Pavlidis, N.
Nicolaides, C.
Athanassiadis, A.
Beriatou, K.
Skarlos, D.
Giannakakis, T.
Kosmidis, P.
Karvounis, N.
Fountzilas, G.

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Type of the conference item

Journal type

peer-reviewed

Educational material type

Conference Name

Journal name

Oncology

Book name

Book series

Book edition

Alternative title / Subtitle

Description

Preclinical data have shown a synergism between 5-fluorouracil and interferon-gamma against human colon carcinoma cell lines. We conducted a phase II trial of this combination in 34 patients with metastatic colorectal cancer. 5-Fluorouracil was administered as an intravenous bolus of 500 mg/m2 weekly and interferon-gamma subcutaneous injection at a dose of 200 micrograms (6 x 10(6) IU) 3 times a week. Thirty-two patients were evaluable for response. There was one complete and two partial responses (response rate 9.0%, 95% CI 1.98-25.02%). Eleven patients (34%) had stable disease. Common toxicities included fever 81%, nausea/vomiting 19%, diarrhea 16%, flu-like syndrome 16%, malaise 12.5% and leukopenia 12.5%. These results indicate that the above combination of 5-fluorouracil and interferon-gamma has an unimpressive activity in patients with advanced colorectal carcinoma. Toxicity was very tolerable.

Description

Keywords

Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Colorectal Neoplasms/*drug therapy, Female, Fluorouracil/administration & dosage/adverse effects, Humans, Interferon-gamma/administration & dosage/adverse effects, Male, Middle Aged, Neoplasm Metastasis, Prospective Studies, Treatment Outcome

Subject classification

Citation

Link

http://www.ncbi.nlm.nih.gov/pubmed/8604243
http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000227553

Language

en

Publishing department/division

Advisor name

Examining committee

General Description / Additional Comments

Institution and School/Department of submitter

Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής

Table of contents

Sponsor

Bibliographic citation

Name(s) of contributor(s)

Number of Pages

Course details

Endorsement

Review

Supplemented By

Referenced By